Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score.
Syed Sa GilaniNisha NairDarren PlantKimmie L HyrichAnn W MorganAndrew P MorrisAnthony G WilsonJohn Dudley IsaacsRichard B WarrenJames Bluettnull nullPublished in: Pharmacogenomics (2020)
Aim: TNF inhibitor drugs are a treatment option for rheumatoid arthritis, but response is not universal. Response is typically measured using the composite 4-component (4C) disease activity score 28 (DAS28) which contains more subjective measures. This study used a validated 2-component (2C) DAS28 score to determine whether SNPs associated with response were replicated in the UK population. Materials & methods: A literature review identified TNF inhibitor response SNPs. Linear regression was conducted to replicate associations with 4C or 2C-DAS28 response. Results: Eighteen independent SNPs were analyzed in 1828 patients. One and four associations with 4C and 2C-DAS28 response respectively were identified (p ≤ 0.05). Conclusion: Further genetic associations were replicated using the 2C-DAS28 which may reflect the objective nature of 2C-AS28.
Keyphrases
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- genome wide
- end stage renal disease
- prognostic factors
- cross sectional
- depressive symptoms
- dna methylation
- patient reported
- physical activity
- smoking cessation
- idiopathic pulmonary fibrosis
- peritoneal dialysis
- replacement therapy